Calcineurin inhibitor-free immunosuppression using everolimus (certican) after heart transplantation: 2 years' follow-up from the university hospital Münster

Transplantation Proceedings

Volumn 43, Issue 5, 2011, Pages 1847-1852

  Stypmann, J ^a   Engelen, M A ^a   Eckernkemper, S ^a   Amler, S ^b   Gunia, S ^a   Sindermann, J R ^a   Rothenburger, M ^a   Rukosujew, A ^a   Drees, G ^a   Welp, H A ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; CYCLOSPORIN; CYTOCHROME P450; EVEROLIMUS; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TRIACYLGLYCEROL;

ACNE; ADULT; ANEMIA; ARTICLE; BLOOD SAMPLING; CARDIAC ALLOGRAFT VASCULOPATHY; CARDIAC GRAFT REJECTION; CLINICAL PROTOCOL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIASTOLIC BLOOD PRESSURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ECHOCARDIOGRAPHY; EDEMA; ENDOCARDITIS; FOLLOW UP; GINGIVA HYPERPLASIA; GRAFT RECIPIENT; HEART EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HEART TRANSPLANTATION; HEPATITIS B; HIRSUTISM; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTIOUS PNEUMONIA; INFLUENZA; INTERSTITIAL PNEUMONIA; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; LEUKOPENIA; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MUSCLE CRAMP; PERIPHERAL EDEMA; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHYSICAL EXAMINATION; POSTOPERATIVE CARE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROSPECTIVE STUDY; PYREXIA IDIOPATHICA; RECURRENT DISEASE; RHEUMATIC DISEASE; SIDE EFFECT; SKIN DISEASE; SYSTOLIC BLOOD PRESSURE; TREMOR; TRICUSPID VALVE ENDOCARDITIS; UNIVERSITY HOSPITAL; WEIGHT REDUCTION;

AGED; BLOOD PRESSURE; CALCINEURIN; CREATININE; FEMALE; FOLLOW-UP STUDIES; GERMANY; HEART TRANSPLANTATION; HOSPITALS, UNIVERSITY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SIROLIMUS;

EID: 79959447991     PISSN: 00411345     EISSN: 18732623     Source Type: Journal    
DOI: 10.1016/j.transproceed.2010.12.062     Document Type: Article

References (27)

1. A. Keogh Calcineurin inhibitors in heart transplantation J Heart Lung Transplant s23 5 Suppl 2004 S202
2. Organ Procurement and Transplantation Network reports 19962001 http://www.optn.org
3. J. Lindenfeld, G.G. Miller, and S.F. Shakar Drug therapy in the heart transplant recipient: part II: immunosuppressive drugs Circulation 110 2004 3858
4. T.M. Chapman, and C.M. Perry Everolimus Drugs 64 2004 861 discussion 873
5. H.J. Eisen, E.M. Tuzcu, and R. Dorent Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients N Engl J Med 349 2003 847
6. A.S. Leet, P.J. Bergin, and M. Richardson Outcomes following de novo CNI-free immunosuppression after heart transplantation: a single-center experience Am J Transplant 9 2009 140
7. J. Kobashigawa, L. Miller, D. Renlund Mycophenolate Mofetil Investigators A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients Transplantation 66 1998 507
8. H. Lyster, G. Panicker, N. Leaver, and N.R. Banner Initial experience with sirolimus and mycophenolate mofetil for renal rescue from cyclosporine nephrotoxicity after heart transplantation Transplant Proc 36 2004 3167
9. J. Groetzner, I. Kaczmarek, and B. Meiser Sirolimus and mycophenolate mofetil as calcineurin inhibitorfree immunosuppression in a cardiac transplant patient with chronic renal failure J Heart Lung Transplant 23 2004 770
10. H. Valantine Prevention of cardiac allograft vasculopathy with Certican (everolimus): the Stanford University experience within the Certican phase III clinical trial J Heart Lung Transplant 24 4 Suppl 2005 S191
11. H. Lehmkuhl, and R. Hetzer Clinical experience with Certican (everolimus) in de novo heart transplant patients at the Deutsches Herzzentrum Berlin J Heart Lung Transplant 24 4 Suppl 2005 S201
12. H. Ross, P. Flugfelder, and H. Haddad Cyclosporine reduction in the presence of everolimus: 3-month data from a Canadian pilot study of maintenance cardiac allograft recipients J Heart Lung Transplant 27 2008 197
13. A. Zuckermann Clinical experience with Certican (everolimus) in maintenance heart transplant patients at the Medical University of Vienna J Heart Lung Transplant 24 4 Suppl 2005 S206
14. M. Rothenburger, J. Stypmann, and H. Welp Calcineurin inhibitorfree immunosuppression using everolimus in long term heart transplant recipientsprocedures of switching protocols and side effects J Heart Lung Transplant 25 2006 S166 [abstract 356]
15. M. Rothenburger, E. Teerling, and C. Bruch Calcineurin inhibitorfree immunosuppression using everolimus (Certican) in maintenance heart transplant recipients: 6 months' follow-up J Heart Lung Transplant 26 2007 250
16. N. Brignol, L.M. McMahon, S. Luo, and F.L. Tse High-throughput semi-automated 96-well liquid/liquid extraction and liquid chromatography/mass spectrometric analysis of everolimus (RAD 001) and cyclosporin a (CsA) in whole blood Rapid Commun Mass Spectrom 15 2001 898
17. D.W. Cockcroft, and M.H. Gault Prediction of creatinine clearance from serum creatinine Nephron 16 1976 31
18. Y. Lebranchu, A. Thierry, and O. Toupance Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: CONCEPT study Am J Transplant 9 2009 1115
19. M. Weir, S. Mulgaonkar, and T. Pearson Mycophenolate mofetil/sirolimus maintenance therapy after calcineurin inhibitor withdrawal in renal transplant recipients: 2-year outcomes of the Spare-the-Nephron (STN) trial Am J Transplant 9 2009 200 [abstract 33]
20. K. Budde, T. Becker, and C. Sommerer Analysis of renal function in everolimus/enteric-coated mycophenolate sodium treated de novo renal transplant recipients after calcineurin inhibitor withdrawal: the Zeus Study Am J Transplant 9 2009 259 [abstract 237]
21. C.A. Gleissner, A. Doesch, and P. Ehlermann Cyclosporine withdrawal improves renal function in heart transplant patients on reduced-dose cyclosporine therapy Am J Transplant 6 2006 2750
22. F.P. Schena, M.D. Pascoe, and J. Alberu Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial Transplantation 87 2009 233
23. J. Moro, L. Almenar, and L. Martínez-Dolz mTOR inhibitors and their secondary effects in cardiac transplant recipients: a descriptive study Transplant Proc 39 2007 2365
24. S. Vitko, R. Margreiter, and W. Weimar Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients Am J Transplant 5 2005 2521
25. M. Ayala, J. Morales, and A. Fierro Metabolic changes following conversion from an anticalcineurin-based therapy to an everolimus-based one: a single-center experience Transplant Proc 40 2008 3265
26. G. Tenderich, U. Fuchs, and A. Zittermann Comparison of sirolimus and everolimus in their effects on blood lipid profiles and haematological parameters in heart transplant recipients Clin Transplant 21 2007 536
27. J.A. Moro, L. Almenar, and L. Martínez-Dolz Tolerance profile of the proliferation signal inhibitors everolimus and sirolimus in heart transplantation Transplant Proc 40 2008 3034